NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I HORMONE SENSITIVE HER2-NEGATIVE ONCOTYPE RECURRENCE SCORE = 18 BREAST CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Stage I, Hormone Sensitive, Her2-negative, Oncotype Recurrence Score = 18 Breast Cancer
  • Age: Between 50 - 70 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. The patient must have an ECOG performance status of 0 or 1.
    2. The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and Ductal carcinoma in situ (DCIS) with no ink on tumor as determined by the local pathologist.
    3. The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
    4. The stage of the breast tumor must be pT1N0M0

You may not be eligible for this study if the following are true:

    1. Oncotype recurrence score >18
    2. Definitive clinical or radiologic evidence of metastatic disease.
    3. Patient had a mastectomy.
    4. Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.